Abstract 1178P
Background
Melanoma is the fifth most common cancer and, although rare, is the most common skin malignancy in those under 20 years old in the United States (US), with an average annual incidence rate (IR) of 5.5-6.0 cases per million. Since the 1970s, the incidence of pediatric melanoma has increased with an average annual percent change of 2–2.9% in the US. Epidemiological knowledge and predictors of melanoma among children and adolescents (age < 20 years) in Korea are limited.
Methods
Using data from National Health Insurance (NHI) database, we identified incident melanoma cases diagnosed at 0-19 years old during 2004-2019 in Korea, respectively. Using a joinpoint regression model, associations between demographic factors and melanoma incidence rates (IR) were evaluated by calculating incidence rate ratios and 95% confidence intervals (CI).
Results
We identified a total of 1160 patients (age < 20 years) with cutaneous malignant melanoma from 2004-2019. The overall average annual melanoma incidence was 0.22 per million (95% CI, 0.21-0.23) in Korea. It increased with age (age 0-4: 0.3, age 5-9: 0.6, age 10-14: 0.6, age 15-19: 07 per 100,000 persons) but there was no difference in IR according to sex. The age-adjusted incidence of melanoma decreased 4.5% yearly from 2004 to 2012 (95% CI, -8.9%–0.1%) but increased 12.6% yearly from 2012 to 2019 (95% CI, 5.9%–19.6%). A strong correlation between melanoma IR and nevi was confirmed (OR 85.4, 95% CI 67.97 - 106.40, P < 0.001) and this was also linked to the survival rate (5-year survival rate: 97.7% vs 91.9%, P = 0.044).
Conclusions
Although the incidence of melanoma in children and adolescent is very low, it is clear that it increases in Korea. To our knowledge, this is the first report to suggest that melanoma IR trends in children and adolescent are annually increasing in Korea. Most importantly, we must increase awareness and education amongst pediatricians, internists and the general population with regard to prevention and early diagnosis of melanoma for both children and adults. In addition, the physicians should include a complete skin examination for children with congenital nevi.
Clinical trial identification
none
Editorial acknowledgement
none
Legal entity responsible for the study
Jisu Oh.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1149P - Prognosis for patients with metastatic Merkel cell carcinoma with a complete response on avelumab treatment
Presenter: Lisanne Zijlker
Session: Poster session 13
1150P - Transforming growth factor-beta-1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in advanced basal cell carcinoma
Presenter: Bernardo Rapoport
Session: Poster session 13
1151P - Characteristics and treatment outcomes in cutaneous adnexal carcinomas
Presenter: Adam Rock
Session: Poster session 13
1152P - Association of immune-related adverse events (irAE) requiring glucocorticoids (GCs) with outcome and biomarkers in advanced cutaneous malignant melanoma (CMM) treated with immune checkpoint inhibitors (ICI)
Presenter: Fernanda Costa Svedman
Session: Poster session 13
1153P - Incidence and characteristics of immunotherapy related adrenal insufficiency in a monocenter, pan-cancer cohort of 4314 patients
Presenter: Minke Lucas
Session: Poster session 13
1154P - Thromboembolic events in patients with melanoma receiving immune checkpoint inhibitors: Incidence and risk factors
Presenter: Daan van Dorst
Session: Poster session 13
1155P - Application of novel machine learning to predict immunotherapy related toxicities for metastatic melanoma patients from baseline 18F-FDG PET/CT scans
Presenter: Roslyn Francis
Session: Poster session 13
1156P - Immune-related adverse events in a nationwide cohort of melanoma patients treated with adjuvant anti-PD1: Seasonal variation and association with outcome
Presenter: Eva Ellebæk
Session: Poster session 13
1157P - Corticosteroids and second-line immunosuppressants for immune-related adverse events and melanoma survival
Presenter: Rik Verheijden
Session: Poster session 13
1158P - Association of corticosteroid (CS) exposure with treatment failure in patients (pts) with advanced melanoma treated with immune checkpoint inhibitors (ICIs)
Presenter: Ha Mo Linh Le
Session: Poster session 13